Top Markets
Coin of the day
Immunotech Biopharm Ltd Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

6978
Rangering i aksjer #27803
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in... Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Aksjekurs
$0.0492516
Markedsverdi
$30.41M
Endring (1 dag)
1.32%
Endring (1 år)
-91.28%
Land
CN
Handel Immunotech Biopharm Ltd (6978)

Kategori

Inntekter for Immunotech Biopharm Ltd (6978)
Inntekter i 2026 TTM: 0
Ifølge Immunotech Biopharm Ltd sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Immunotech Biopharm Ltd fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$-3.09B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH